Abstract 5106
Background
Obesity is a well-known risk factor for colorectal cancer (CRC), the relative risk being higher in men than in women, and for colon than for rectal cancer. Whether this risk differs by sidedness of colon cancer and sex, has however not yet been explored.
Methods
Among 28098 participants in the Malmö Diet and Cancer study, 11063 men and 17035 women, 584 incident CRC cases had been registered by Dec 31 2008. Seven anthropometric factors; height, weight, bodyfat%, hip circumference, waist circumference, BMI and waist-hip ratio (WHR) were categorized into quartiles (Q). Hazard ratios (HR) of CRC risk according to tumour location (right colon, left colon, rectum) and sex were calculated using multivariable Cox regression models, adjusted for age, smoking, educational level and alcohol intake.
Results
In men, several anthropometric factors were associated with an increased risk of right-sided colon cancer (HR for Q1[ref]-Q4 for weight 1.0, 1.67, 1.99, 2.88, ptrend= 0.001; waist circumference 1.0, 0.64, 1.59, 2.03, ptrend= 0.002; WHR 1.0, 0.73, 1.93, 1.89, ptrend= 0.004; BMI 1.0, 1.29, 1.50, 2.64, ptrend= 0.001), only WHR with left-sided colon cancer (1.0, 1.26, 1.94, 2.06, ptrend= 0.021), and none with rectal cancer. In women, body size was not associated with risk for neither right-sided nor left-sided colon cancer, only with rectal cancer (bodyfat% 1.0, 1.57, 2.18, 1.94, ptrend= 0.032, hip circumference 1.0, 1.76, 1.45, 2.18, ptrend= 0.033). Significant interactions with sex were denoted for hip circumference (p = 0.032) and BMI (p = 0.026) in relation to risk of right-sided colon cancer.
Conclusions
These data unveil a sexual dimorphism in the relationship between obesity and right-sided colon cancer, only being evident in men. As right-sided tumours are otherwise more common in women, hormonal factors may be particularly influential in their carcinogenesis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Lund University.
Funding
The Swedish Cancer Society, the Swedish Research Council, the Swedish Government Grant for Clinical Research, the Mrs Berta Kamprad Foundation, Lund University Faculty of Medicine and University Hospital Research Grants.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2551 - Efficacy of dose-dense (DD) adjuvant chemotherapy (CT) in hormone receptor positive/HER2-negative early breast cancer (BC) patients (pts) according to immunohistochemically (IHC) defined luminal subtypes: an exploratory analysis of the GIM2 trial.
Presenter: Benedetta Conte
Session: Poster Display session 2
Resources:
Abstract
3426 - High dose Neo-adjuvant chemotherapy in Triple-Negative breast cancer with evidence of homologous recombination deficiency (HRD).
Presenter: Sonja Vliek
Session: Poster Display session 2
Resources:
Abstract
3792 - Risk factors for locoregional recurrence (LRR) after neoadjuvant chemotherapy: pooled analysis of prospective neoadjuvant breast cancer (BC) trials
Presenter: Gustavo Werutsky
Session: Poster Display session 2
Resources:
Abstract
4044 - Estimating radiotherapy-induced cardiovascular mortality in female breast cancer patients.
Presenter: Mark De Ridder
Session: Poster Display session 2
Resources:
Abstract
719 - 3-year follow-up of a phase III trial comparing the efficacy and safety of neoadjuvant and adjuvant trastuzumab and its biosimilar CT-P6 in HER2 positive early breast cancer (EBC)
Presenter: Justin Stebbing
Session: Poster Display session 2
Resources:
Abstract
3595 - Adjuvant chemotherapy in elderly breast cancer patients: pattern of use and impact on overall survival
Presenter: Axel Berthelot
Session: Poster Display session 2
Resources:
Abstract
3992 - Carboplatin-containing neoadjuvant chemotherapy for triple negative breast cancer (TNBC): a propensity score-matched study.
Presenter: Maria Vittoria Dieci
Session: Poster Display session 2
Resources:
Abstract
3477 - Impact of adjuvant trastuzumab emtansine (T-DM1) on incidence of metastatic breast cancer (mBC): an epidemiological model of patients with HER2-positive breast cancer (BC) who did not achieve pathological complete response (pCR) after neoadjuvant treatment (non-pCR)
Presenter: Mellissa Williamson
Session: Poster Display session 2
Resources:
Abstract
3928 - Chemotherapy (CT)-induced anaemia in patients (pts) treated with dose-dense regimen: Results of the prospectively randomised anaemia substudy from the neoadjuvant GeparOcto study
Presenter: Hans Tesch
Session: Poster Display session 2
Resources:
Abstract
2184 - The clinical impact of adjuvant dose-dense sequential chemotherapy (dds-CT) in patients with high-risk operable breast cancer (BC); pooled analysis of 6 clinical trials.
Presenter: Elena Fountzilas
Session: Poster Display session 2
Resources:
Abstract